Year in Review | Published:

Osteoarthritis in 2017

Latest advances in the management of knee OA

Nature Reviews Rheumatology volume 14, pages 7374 (2018) | Download Citation

Osteoarthritis research in 2017 provided new insights into the long-term effects of intra-articular glucocorticoids, and also led to the approval of a novel, longer-lasting glucocorticoid formulation. New drugs for the treatment of osteoarthritis also emerged this year, including a small-molecule inhibitor of the Wnt signalling pathway.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Flexion Therapeutics Inc. Zilretta (triamcinolone acetonide extended-release injectable suspension), for intra-articular use [label] Food and Drug Administration (2017).

  2. 2.

    et al. Effect of intra-articular triamcinolone versus saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317, 1967–1975 (2017).

  3. 3.

    et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage 25, 1598–1606 (2017).

  4. 4.

    et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22, 363–388 (2014).

  5. 5.

    et al. An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J. Bone Joint Surg. Am. 97, 877–888 (2015).

  6. 6.

    et al. Phase 2b trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intra-articular injection in knee osteoarthritis. Arthritis Rheumatol. (2017).

  7. 7.

    et al. Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann. Rheum. Dis. 63, 1124–1127 (2004).

  8. 8.

    , et al. Risk factors for joint replacement in knee osteoarthritis; a 15-year follow-up study. BMC Musculoskelet. Disord. 18, 510 (2017).

  9. 9.

    et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 26, 18–27 (2018).

  10. 10.

    et al. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann. Intern. Med. 163, 365–372 (2015).

Download references

Acknowledgements

The work of T.E.M. is supported by the NIH. The work of R.R.B. is supported by the NIH National Center for Complementary and Integrative Health (NCCIH). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NCCIH.

Author information

Affiliations

  1. Timothy E. McAlindon and Raveendhara R. Bannuru are at the Center for Treatment Comparison and Integrative Analysis (CTCIA), Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Boston, Massachusetts 02111, USA.

    • Timothy E. McAlindon
    •  & Raveendhara R. Bannuru

Authors

  1. Search for Timothy E. McAlindon in:

  2. Search for Raveendhara R. Bannuru in:

Competing interests

T.E.M. declares that he has acted as a consultant for Flexion Therapeutics and as an Advisory Board member for Samumed. R.R.B. declares no competing interests.

Corresponding author

Correspondence to Timothy E. McAlindon.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2017.219

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing